Arvita Tripati is a healthcare AI executive and board director with nearly two decades of experience bringing regulated products from concept to enterprise adoption across biopharma, medtech, and digital health. She has led the development and scale of over 30 products—including 10 AI-driven solutions—consistently addressing the gap between successful pilots and stalled enterprise deals, particularly in highly regulated environments. She has held senior roles across organisations such as Gilead, the NHS, AliveCor, and Korio Clinical, where she built and scaled product, engineering, and regulatory functions from the ground up. Her work includes enabling the first commercially approved CAR-T therapy in the U.S., expanding AI-enabled cardiac devices internationally, and driving significant revenue growth across multiple organisations. She is particularly known for navigating FDA-regulated environments, leading compliance and inspection processes, and embedding trust into AI deployment at scale. Currently, Arvita leads Vahana Labs, advising healthtech and AI companies on bridging the gap between pilot success and enterprise contracts, as well as supporting investors with technical due diligence in regulated AI. She also serves on boards and audit committees, contributing to AI governance, risk, and product strategy at the highest levels.